Is surgical restaging indicated in apparent stage IA pure ovarian dysgerminoma? the MITO group retrospective experience

G. Mangili, C. Sigismondi, D. Lorusso, G. Cormio, P. Scollo, R. Viganò, T. Gamucci, M. Candiani, S. Pignata

Research output: Contribution to journalArticlepeer-review


Objective: Conservative surgery followed by platinum-based chemotherapy is considered the standard approach for pure ovarian dysgerminoma (POD), except for correctly staged IA patients. The aim of study was to evaluate the outcome of IA POD patients with incomplete surgical staging in order to define the proper management. Methods: Data concerning primary treatment and recurrence were reviewed for 26 patients with stage IA POD treated in MITO (Multicenter Italian Trials in Ovarian Cancer) centers. Results: Median age was 22.5 years. Primary surgery was fertility sparing for 17 patients (65.4%) and radical surgery was performed in 9 patients due to older age or gonadal dysgenesis. Only five patients (19.2%) had complete surgical staging; 38.5% had lymph node dissection, 46.2% had peritoneal biopsies and/or omentectomy and 65.4% had peritoneal washing. Seven patients received adjuvant chemotherapy. Overall recurrence rate was 11.5%: all recurrences occurred in the group submitted to incomplete staging procedure. No patients treated with adjuvant chemotherapy relapsed. One patient had pelvic recurrence, one patient relapsed in the abdomino-pelvic peritoneum and lymph nodes and the third patient showed a peritoneum, lymph nodal and residual ovary relapse. All patients with recurrence were cured by salvage therapy: 2 patients were treated with surgery plus chemotherapy and one only with chemotherapy. After a median follow-up of 100 months all patients are alive without evidence of disease. Six patients opted for conception and delivered healthy infants, two with IVF with donor oocyte. Conclusions: IA POD prognosis is excellent. Conservative surgery with a complete surgical staging is the gold standard. Patients with incomplete staging could undergo surgical restaging or surveillance. Chemotherapy should be reserved to relapse with excellent chances of therapeutic success.

Original languageEnglish
Pages (from-to)280-284
Number of pages5
JournalGynecologic Oncology
Issue number2
Publication statusPublished - May 1 2011


  • Chemotherapy
  • Ovarian dysgerminoma
  • Recurrence
  • Stage IA
  • Surgical restaging

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Oncology


Dive into the research topics of 'Is surgical restaging indicated in apparent stage IA pure ovarian dysgerminoma? the MITO group retrospective experience'. Together they form a unique fingerprint.

Cite this